Ozlem Terzi, Ali Aycicek, Ezgi Uysalol, Duygu Yildirgan, Fatma Sek, Cengiz Bayram


Introduction: Although high-dose Methotrexate (MTX) is a successful chemotherapeutic agent used in the treatment of acute lymphoblastic leukemia in childhood, life-threatening toxic effects are rarely seen. Therefore, frequent follow-up of drug levels is recommended. The study researched the necessity of drug level measurement and a minimum safe number of measurements.

Materials and Methods: The files of pediatric patients with Acute Lymphoblastic Leukemia receiving high-dose MTX treatment in a single center between 2018 and 2021 were retrospectively reviewed. The treatment protocol was: 3000 mL/m2 alkaline hydration fluid was continued until the 72nd hour together with 2 gr/m2 continuous MTX infusion in the low-risk group and 5 gr/m2 in moderate and high-risk groups, and 15 mg/m2/dose folinic acid was given at the 42nd, 48thand 54th hours.

Findings: 456 MTX treatments were evaluated in 114 patients. Similar results (p>0.05) were obtained in the MTX level measurements performed at the 24th, 42nd, 48th, and 54th hours after MTX administration. In the repeated measurements, the data at the 42nd hour were similar (p=0.021). The number of cases that were >150 mmol/L at the 24th hour of methotrexate infusion and above 1 mmol/L at the 42nd, 48th, and 52nd hours were found to be similar in the repeated measurements.

Conclusion: Although recommended, frequent follow-up of MTX levels might not always indicate toxicity. In centers with limited laboratory facilities, the MTX level measured at the 42nd hour in the first treatment might be a practical approach to guide the management of other MTX treatments.


leukemia, methotrexate, toxicity, drug level

Full Text:



Pui CH, Relling MV, Evans WE. Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia? Leuk Lymphoma.2006; 47(12): 2431-2. doi: 10.1080/10428190600955837.

Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children’s Oncology Group. Blood. 2011; 118(4):874–83.

doi: 10.1182/blood-2010-06-292615

Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk. B-acute lymphoblastic leukemia: A report from Children’s Oncology Group Study AALL0232. J Clin Oncol.2016;34(20):2380–8. doi: 10.1200/JCO.2015.62.4544.

Fotoohi K, Skarby T, Soderhall S, Peterson C, Albertioni F. Interference of 7-hydroxymethotrexate with the determination of methotrexate in plasma samples from children with acute lymphoblastic leukemia employing routine clinical assays. J Chromatogr B Anal Technol Biomed Life Sci.2005; 817(2):139 – 44. doi: 10.1016/j.jchromb.2004.11.037

Skarby TV, Anderson H, Heldrup J, Kanerva JA, Seidel H, Schmiegelow K. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia.2006; 20(11):1955-62. doi: 10.1038/sj.leu.2404404.

Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood.2000;95(11):3310-22.

Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood.2008;111(9):4477-89. doi: 10.1182/blood-2007-09-112920.

Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med. 1986;314(8):471–7.

doi: 10.1056/NEJM198602203140803

Howard SC, McCormick J, Pui C-H, Buddington RK, Harvey RD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471-82. doi: 10.1634/theoncologist.2015-0164.

Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity.Oncologist.2006;11(6):694–703. doi: 10.1634/theoncologist.11-6-694.

Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharmacol. 1979;3(3): 161-6. doi: 10.1007/BF00262416.

Vaishnavi K, Bansal D, Trehan A, Jain R, Attri SV. Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin. Pediatr Blood Cancer. 2018;65(12): e27241.

doi: 10.1002/pbc.27241.

Howard SC, Pedrosa M, Lins M, Pedrosa A, Pui CH, Ribeiro RC, et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA. 2004; 291(20):2471–5. doi: 10.1001/jama.291.20.2471

Dhingra H, Kalra M, Mahajan A. Safe administration of high-dose methotrexate with minimal drug level monitoring: Experience from a center in north India. Pediatr Blood Cancer. 2020;67(11): e28394.

doi: 10.1002/pbc.28394

Aumente D, Buelga DS, Lukas JC, Gomez P, Torres A, Garcia MJ. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukemia. Clin Pharmacokinet. 2006; 45(12):1227- 38.

doi: 10.2165/00003088-200645120-00007.

Plard C, Bressolle F, Fakhoury M, Zhang D, Yacouben K, Rieutord A, et al. A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2007; 60(4):609-20.

doi: 10.1007/s00280-006-0394-3.

Pui C-H, Sandlund JT, Pei D, Campana D, Rivera GK, Ribeiro RC, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004;104(9): 2690-6. doi: 10.1182/blood-2004-04-1616.

Rolim-Neto LM, Reis AOA, de Carvalho FMS, Moreira MM, Ramalho-Filho NCH, Lima RNN, et al. Vulnerability and the bioethics through the experiences of illness. Sanamed. 2012;7(2):107-12.

Widemann BC, Schwartz S, Jayaprakash N, Christensen R, Pui CH, Chauhan N, et al. Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high‐dose methotrexate therapy. Pharmacotherapy. 2014;34(5): 427–39. doi: 10.1002/phar.1360.

Sari NM, Rakhmilla LE, Bashari MH, Zazuli Z, Suryawan N, Susanah S, et al. Monitoring of high-dose methotrexate (Mtx)-related toxicity and Mtx levels in children with acute lymphoblastic leukemia: a pilot-study in Indonesia. Asian Pac J Cancer Prev. 2021; 22(7):2025-31.

doi: 10.31557/APJCP.2021.22.7.2025.

Skärby T, Jönsson P, Hjorth L, Behrentz M, Björk O, Forestier E, et al. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother Pharmacol. 2003; 51(4):311-20.

doi: 10.1007/s00280-002-0552-1.

XuW, Zhang L, Chen X, Pan BH, Mao JQ, Song H, et al. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies. Cancer Chemother Pharmacol. 2014; 73(1):79–86. doi: 10.1007/s00280-013-2319-2.

Tiwari P, Thomas MK, Pathania S, Dhawan D, Gupta YK, Vishnubhatla S, et al. Serum creatinine versus plasma methotrexate levels to predict toxicities in children receiving high dose methotrexate. Pediatr Hematol Oncol. 2015; 32(8):576-84. doi: 10.3109/08880018.2015.1087612.

Yang SL, Zhao FY, Song H, Shen DY, Xu XJ. Methotrexate associated renal impairment is related to delayed elimination of high-dose methotrexate. Sci World J. 2015; 2015:751703. doi: 10.1155/2015/751703.

Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology, and prevention / therapy. Semin Nephrol. 2010; 30(6):570–81. doi: 10.1016/j.semnephrol.2010.09.005.

Khera S, Kapoor R, Pramanik SK. Solitary serum methotrexatelevel 36 hours post high dose methotrexate: A safe, efficacious, and cost-effective strategy to monitör methotrexate toxicities in childhood leukemia in resource-limited centers. Pediatr Blood Cancer. 2020; 67(7): e28387.

doi: 10.1002/pbc.28387.

Kapoor G, Sinha R, Abedin S. Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country. Pediatr Blood Cancer. 2012; 59(3):448–53. doi: 10.1002/pbc.24081.

Sajith M, Pawar A, Bafna V, et al. Serum methotrexate level and side effects of high dose methotrexate infusion in pediatric patients with acute lymphoblastic leukaemia (ALL). Indian J Hematol Blood Transfus. 2020; 36(1):51-8. doi: 10.1007/s12288-019-01144-3.

Sonis ST. A biological approach to mucositis. J Support Oncol 2004; 2:21–32; discussion 35–6.

Schmidt E, Thoennissen NH, Rudat A, Bieker R, Schliemann C, Mesters RM, et al. Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. Ann Oncol. 2008; 19(9):1644–9.

doi: 10.1093/annonc/mdn179.

Maiguma T, Kaji H, Makino K, Teshima D.. Protective effects of amifostine and cyclooxygenase-1 inhibitor against normal human epidermal keratinocyte toxicity induced by methotrexate and 5-fluorouracil. Basic Clin Pharmacol Toxicol. 2009; 105(1):1–9. doi: 10.1111/j.1742-7843.2009.00400.x.

DOI: http://dx.doi.org/10.5937/sanamed17-40079


  • There are currently no refbacks.

Copyright (c) 2022 Ozlem Terzi, Ali Aycicek, Ezgi Uysalol, Duygu Yildirgan, Fatma Sek, Cengiz Bayram

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.